ILMN
Illumina, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$215.31
−2.87%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
37.7x
EV/EBITDA
24.8x
Market Cap
$32.51B
MomentumView details →
1D Return
−2.87%
YTD Return
+65.22%
RSI (14)
58.8
ValuationView details →
P/E (Fwd)
37.7x
EV/EBITDA
24.8x
Market Cap
$32.51B
RSI (14)
58.8
MomentumView details →
1D Return
−2.87%
YTD Return
+65.22%
SummaryUpdated Jun 1, 2026
Illumina, Inc. (NASDAQ:ILMN) is a leading biotechnology company founded in 1998 and based in San Diego, California, that went public in 2000. The company pioneered the development of DNA sequencing and array-based solutions that have revolutionized genetic and genomic analysis. Over its 25+ year history, Illumina has established itself as the dominant player in the DNA sequencing market, providing the foundational technology that enables genomic research, clinical diagnostics, and personalized medicine applications worldwide.
Similar companies
Latest newsMore news →
Biondo Investment Advisors LLC acquired a new minority stake in Illumina, Inc. by purchasing 10,630 shares valued at approximately $1.87 million, as disclosed in a 13F filing.11d agoAllworth Financial LP acquired a new position in Illumina, Inc. by purchasing 5,976 shares valued at approximately $1,051,000 in the second quarter, as disclosed in its 13F filing.12d agoIllumina, Inc. entered into a new $1 billion senior unsecured five-year revolving credit facility with a syndicate of lenders led by Bank of America, N.A., JPMorgan Chase Bank, N.A., Citibank, N.A., and Goldman Sachs Bank USA, and terminated its existing 2023 credit agreement.23d ago